Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021.

Clin Infect Dis · 2022 · PMC8992305 · PMID 35279028

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

barely significantP = .05actually significant

Among never-infected participants, younger age was associated with higher GMC post dose 1 (T1) ( Table 2 , P < .001) but the difference in GMC was barely significant by T5 (7–9 months post dose 1 but prior to dose 3, Table 2 and Figure 1 , P = .05).

also in 875 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.